{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:46:16Z","timestamp":1779162376330,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]},{"name":"Ministry of Health, Labour, and Welfare Policy Research Grants","award":["202406039A"],"award-info":[{"award-number":["202406039A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe the temporal trends in the prescription of biologics in Japan, with additional analysis focusing on switching from original biologics to biosimilars at the individual and institutional levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the JMDC claims database from January 2005 to May 2024, we identified patients who received at least one prescription for 17 biologics (original biologics or biosimilars). We elucidated the monthly trends in the proportions of original biologics and biosimilars. We also estimated the proportion of patients receiving original biologics only, those receiving biosimilars only, and those switching from original biologics to biosimilars (and vice versa) during the study period. Finally, we estimated the proportion of medical institutions that started prescribing biosimilars during the study period based on the type of medical institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Temporal trends in the proportions of original biologics and biosimilars varied widely. In May 2024, the proportion of biosimilar prescriptions was 13.6% for somatropin and 92.5% for filgrastim. At the individual level, the proportion of patients switching from original biologics to biosimilars was low (1.2\u201314.0%), indicating that switches do not often occur within the same patient, while more recent new users of biologics start biosimilars. At the institutional level, university-related hospitals and clinics were more and less likely, respectively to introduce biosimilars than public and other types of hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Temporal trends in the prescription of biosimilars and switching patterns varied widely by the type of biologics. The type of medical institution should be considered when assessing and promoting the use of biosimilars. Further research and strategies to increase the use of biosimilars in clinics may be needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-025-00850-7","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:42:40Z","timestamp":1754523760000},"page":"1276-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan"],"prefix":"10.1007","volume":"59","author":[{"given":"Minako","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuko","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiko","family":"Adomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"850_CR1","unstructured":"Annual Health, Labour and Welfare Report 2021. https:\/\/www.mhlw.go.jp\/english\/wp\/wp-hw14\/dl\/02e.pdf"},{"key":"850_CR2","first-page":"4","volume":"09","author":"M Kleinstauber","year":"2024","unstructured":"Kleinstauber M. The role of generic medicines in reducing healthcare costs. J Adv Pract Nurs. 2024;09:4\u20135.","journal-title":"J Adv Pract Nurs"},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","volume":"38","author":"C Rieger","year":"2024","unstructured":"Rieger C, Dean JA, Hall L, et al. Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review. BioDrugs. 2024;38:541\u201355.","journal-title":"BioDrugs"},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"108305","DOI":"10.1016\/j.intimp.2021.108305","volume":"101","author":"SZ Mirjalili","year":"2021","unstructured":"Mirjalili SZ, Sabourian R, Sadeghalvad M, et al. Therapeutic applications of biosimilar monoclonal antibodies: systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. Int Immunopharmacol. 2021;101:108305.","journal-title":"Int Immunopharmacol"},{"key":"850_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s12325-019-00998-3","volume":"36","author":"Y Liu","year":"2019","unstructured":"Liu Y, Yang M, Garg V, et al. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36:1851\u201377.","journal-title":"Adv Ther"},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.dmpk.2018.11.004","volume":"34","author":"A Ishii-Watabe","year":"2019","unstructured":"Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019;34:64\u201370.","journal-title":"Drug Metab Pharmacokinet"},{"key":"850_CR7","unstructured":"The Impact of Biosimilar Competition. Available from: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/03\/IMS-Impact-of-Biosimilar-Competition-2015.pdf"},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00970","volume":"11","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kwon H, Godman B, et al. Uptake of biosimilar In fl iximab in the UK, France, Japan, and Korea\u202f: budget savings or market expansion across countries\u202f? Front Pharmacol. 2020;11:1\u201312.","journal-title":"Front Pharmacol"},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","volume":"10","author":"K Sarnola","year":"2020","unstructured":"Sarnola K, Merikoski M, Jyrkk\u00e4 J, et al. Physicians\u2019 perceptions of the uptake of biosimilars\u202f: a systematic review. BMJ Open. 2020;10:e034183.","journal-title":"BMJ Open"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40259-023-00620-7","volume":"37","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang Z, Wang X, et al. Patients\u2019 perceptions of biosimilars: a systematic review. BioDrugs. 2023;37:829\u201341.","journal-title":"BioDrugs"},{"key":"850_CR11","first-page":"102","volume":"25","author":"E Leonard","year":"2019","unstructured":"Leonard E. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25:102\u201312.","journal-title":"J Manag Care Spec Pharm"},{"key":"850_CR12","first-page":"10","volume":"1221","author":"H Sakamaki","year":"2023","unstructured":"Sakamaki H. Considering the sustainability of biosimilars in Japan. Int Pharm Intell. 2023;1221:10\u20135 ((in Japanese)).","journal-title":"Int Pharm Intell"},{"key":"850_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1248\/yakushi.21-00216","volume":"142","author":"R Aoki","year":"2022","unstructured":"Aoki R, Sai K, Katsuta Y, et al. Questionnaire survey on adoption and prescription of biosimilars (antibody and its-related products) by medical doctors in Japan. Yakugaku Zasshi. 2022;142:547\u201360 ((in Japanese)).","journal-title":"Yakugaku Zasshi"},{"key":"850_CR14","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1080\/14796694.2024.2352405","volume":"20","author":"JA Roth","year":"2024","unstructured":"Roth JA, Rahshenas M, Nowacki G, et al. A descriptive analysis of real-world oncology biosimilar use in Japan. Futur Oncol. 2024;20:1837\u201350.","journal-title":"Futur Oncol"},{"key":"850_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jgf2.367","volume":"21","author":"K Nagai","year":"2020","unstructured":"Nagai K, Tanaka T, Kodaira N, et al. Data resource profile: JMDC claims databases sourced from medical institutions. J Gen Fam Med. 2020;21:211\u20138.","journal-title":"J Gen Fam Med"},{"key":"850_CR16","unstructured":"WHO. Guideline for ATC classification and DDD assignment 2024."},{"key":"850_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.37737\/ace.24011","volume":"6","author":"H Yasunaga","year":"2024","unstructured":"Yasunaga H. Updated information on NDB. Ann Clin Epidemiol. 2024;6:73\u20136.","journal-title":"Ann Clin Epidemiol"},{"key":"850_CR18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1208\/s12249-018-1073-5","volume":"19","author":"Z Gulsen Oner","year":"2018","unstructured":"Gulsen Oner Z, Polli JE. Authorized generic drugs: an overview. AAPS PharmSciTech. 2018;19:2450\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"850_CR19","unstructured":"International Diabetes Federation. https:\/\/diabetesatlas.org\/data-by-location\/country\/japan\/"},{"key":"850_CR20","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","volume":"33","author":"H Cohen","year":"2017","unstructured":"Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33:2160\u201372.","journal-title":"Adv Ther"},{"key":"850_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","volume":"10","author":"I Jacobs","year":"2016","unstructured":"Jacobs I, Singh E, Sewell KL. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adher. 2016;10:937\u201348.","journal-title":"Patient Prefer Adher"},{"key":"850_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","volume":"4","author":"MF Rezk","year":"2017","unstructured":"Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4:209\u201318.","journal-title":"Rheumatol Ther"},{"key":"850_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5649\/jjphcs.42.499","volume":"42","author":"H Maruyama","year":"2016","unstructured":"Maruyama H, Miyake S, Kurokawa T. Does use of a biosimilar product reduce the expenditure of patients? Japanese J Pharm Health Care Sci. 2016;42:499\u2013511.","journal-title":"Japanese J Pharm Health Care Sci"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:17:52Z","timestamp":1762028272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00850-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.06.09.25329307","asserted-by":"object"}]},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HM received consulting fees from GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Janssen Pharmaceutical K.K., Biogen Japan Ltd., Takeda Pharmaceutical Co., Ltd., TEIJIN Pharma Ltd., Hisamitsu Pharmaceutical Co., Inc., and Otsuka Pharmaceutical Co., Ltd. RS received consulting fees from Nippon Kayaku Co. Ltd. MI\u2019s Department of Digital Health, Institute of Medicine, University of Tsukuba, is conducting joint research with JMDC Inc., with funding from JMDC Inc. The funders played no role to conduct the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}